Atea Pharmaceuticals Confirms Receipt Of Unsolicited Proposal From Tang Capital Partners' Affiliate, Concentra Biosciences To Acquire Co. For $5.75/Share In Cash Plus CVR
Portfolio Pulse from Bill Haddad
Atea Pharmaceuticals has received an unsolicited proposal from Tang Capital Partners' affiliate, Concentra Biosciences, to acquire the company for $5.75 per share in cash plus a contingent value right (CVR).
May 23, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atea Pharmaceuticals' stock may be impacted by the unsolicited acquisition proposal from Concentra Biosciences at $5.75 per share in cash plus a contingent value right.
The unsolicited acquisition proposal from Concentra Biosciences at $5.75 per share in cash plus a contingent value right (CVR) is likely to have a positive impact on Atea Pharmaceuticals' stock (AVIR) in the short term. Investors may see this as an opportunity to capitalize on the potential acquisition, driving the stock price up.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100